The objective of the study was to assess the long-term outcome and impact of stem cell source in patients with acute myelogenous leukemia (AML) who received ASCT in first complete remission (CR). A total of 101 patients (median age 46 years) were included in the study. Cytogenetic categories distribution was: favorable: 18%, intermediate: 42%, and unfavorable: 7%. More than one induction course was needed for CR in 21% of patients. In all, 78% of patients had received at least one course of high-dose ara-C before autologous stem cell transplantation (ASCT). Bone marrow (n ¼ 58) or peripheral blood stem cells (PBSC) (n ¼ 43) transplantation was performed at a median of 3.5 months from CR. Hematologic recovery and hospitalization duration were significantly reduced in the PBSC group. No toxic death was recorded in this group. The median follow-up of survivors is 67 months (range: 15-183). The 6-year survival, disease-free survival (DFS), and relapse probabilities are 44%, 38%, and 54%, respectively. The presence of a favorable karyotype and the use of PBSC are independently associated to better survival, and DFS by multivariate analysis. Our results confirm that long-term DFS can be achieved with high-dose chemotherapy and ASCT in patients with AML. They show that use of PBSC is associated to very low mortality rate and acceptable morbidity and contributes to an improvement of autotransplant results.
Current chemotherapy regimens based on a combination of anthracyclines and cytosine-arabinoside (ara-C) lead to complete remission (CR) rates of 60-80% in patients of less than 60 years with newly diagnosed acute myelogenous leukemia (AML). 1 However, a majority of patients relapse, and only 25-35% of those unable to receive allogeneic stem cell transplantation (SCT) achieve long-term disease-free survival (DFS). 2, 3 Post-remission chemotherapy intensification has proved useful for improving patient outcome. This can be performed using high-dose ara-C (HDAC), 2, 4 high-dose alkylating agents with autologous stem cell transplantation (ASCT), 5, 6 or both. Over the past 10 years, several multicenter prospective studies were undertaken to demonstrate the superiority of ASCT over 'conventional' chemotherapy regimens. 3, [7] [8] [9] [10] Overall, these studies showed that ASCT provided a better relapse prevention that translated into improved DFS in some but not all studies. 3, 7 There was also an excess of nonrelapse mortality in the transplant groups and survival was not improved. 3, [7] [8] [9] [10] Recently, peripheral blood stem cells (PBSC) have replaced bone marrow (BM) grafts for ASCT in current practice. We have previously shown that in patients treated for lymphomas or solid tumors, use of PBSCs leads to a faster granulocyte and platelet recovery, a shorter hospitalization duration, and to reduced costs when randomly compared with use of BM. 11 Several studies have demonstrated the feasibility of PBSC transplantation in patients treated for AML. 12, 13 Since delayed engraftment is a major cause of morbidity and nonrelapse mortality after autologous BMT in AML, 5 improvement of hematopoietic recovery may have an impact on the outcome of patients with AML. However, some concern has been raised about the possibility that contamination by leukemic cells might be higher in PBSC grafts. 5, [14] [15] [16] The aim of the present study was to assess the long-term outcome of patients who received ASCT for AML in first CR. We report the results of 101 patients treated in a single institution. The analysis was conducted with a 6-year median follow-up, and focused on the evaluation of prognostic factors and on the impact of PBSC grafts on the final outcome.
Patients and methods

Patient selection
To be eligible for this study, patients had to (1) be aged from 15 to 60 years, (2) have a diagnosis of AML according to FAB criteria, 17 (3) be in first CR at the time of ASCT according to the NCI criteria, 18 (4) have been transplanted before 1998 to ensure a 36-month minimum follow-up. A total of 101 consecutive patients transplanted between November 1984 and November 1998 in our center fulfilled the above criteria. During the study period, all the patients treated in our center for AML who were not eligible for allogeneic BMT were scheduled to ASCT, except for the 1994-1990 time period during which some patients were randomly assigned to receive maintenance chemotherapy according to BGM84 and BGMT87 protocols, 19 and except for patients with acute promyelocytic leukemia (APL) treated after 1993.
The characteristics of the 101 patients are summarized in Table 1 . The series includes four patients with APL (three out of four did not receive all-trans-retinoic acid). All the patients had received a similar induction treatment, which consisted of daunorubicine 60 mg/m 2 /day for 3 days and ara-C 100 mg/ m 2 /day for 10 days. 10, 19 A second course of induction therapy identical to the first was given to the 21 patients who failed the first course. Once in remission, the patients received one course of consolidation therapy (daunorubine and ara-C). According to the different protocols used over the study period, 10, 19 79 patients (78%) received one (72 patients) or two (seven patients) intensification courses with HDAC (3 g/ m 2 Â 8 doses) prior to transplantation.
Stem cell harvesting and processing
Stem cell source was BM for the patients treated before 1994 (58 patients) and PBSC for the patients treated thereafter (43 patients). The two groups did not differ according to the clinical and biological parameters presented in Table 1 . BM grafts were harvested after the consolidation course using standard procedure 20 and contained a median of 2.5 Â 10 8 mononuclear cells. In all, 42 patients received G-CSF-mobilized PBSC. For all these patients, mobilization consisted of G-CSF 5 mg/kg/day starting on day 14 following the first intensification course. Apheresis started when WBC reached 1 Â 10 9 /l, and CD34 þ cells reached 20/ml. A total of 17 patients (40%) for whom the target number of 3 Â 10 6 /kg CD34 þ was not obtained were given a second mobilization course with G-CSF 10 mg kg day starting at hematologic steady state. Overall, a median of two aphereses per patient (range: 1-7) were performed. The grafts contained a median of 5.8 Â 10 6 CD34 þ cells/kg (range: 2.5-12.8). BM and PBSC grafts were cryopreserved and thawed using standard techniques before infusion to patients. 21 
Transplantation
ASCT was performed at a median of 5 months after diagnosis (range: 3-8) and 3.5 months (range: 1.5-9) after CR. Three conditioning regimens were used during the study period. Patients treated between 1984 and 1987 (17 patients) received melphalan 140 mg/m 2 as described. 20 From 1990 to September 1994 (36 patients), they received cyclophosphamide 120 mg/kg and total body irradiation (Cy-TBI regimen). Patients treated between 1987 and 1990 and those treated between September 1994 and April 1998 (48 patients) received busulfan 16 mg/kg p.o. over 4 days and melphalan 140 mg/m 2 (BuMel regimen). 19 After ASCT, seven patients received interleukin-2 after ASCT as previously described. 22 No other post transplant treatment was given to the remaining patients.
Statistical analysis
Analysis was performed as of October 2002. Patients' characteristics and risk groups were compared using w 2 test or Mann-Whitney U-test when appropriate. Overall survival and DFS were calculated from the time of transplant according to the method of Kaplan and Meier, 23 and comparisons were made using the log-rank test. Cumulative incidence of relapse and transplant-related mortality (TRM) were calculated as described. 24 The following factors were analyzed for their impact on outcome: age (X30 years vs o30 years), sex, WBC at diagnosis (X30 Â 10 9 /l vs o30 Â 10 9 /l), number of induction courses for CR (one vs more than one), number of courses of HDAC prior to transplant (none vs one or more), stem cell source (PBSC vs BM), conditioning regimen (TBI-containing vs without TBI), interval from diagnosis to transplant (p5 months vs 45 months), and cytogenetic categories (favorable vs intermediate vs unfavorable). Cytogenetic categories were defined as (1) favorable: t(15;17), t(8;21) and inv (16) , (2) Multivariate analysis was performed using Cox proportional hazard model. 26 Only patients with cytogenetic information available were considered in the multivariate analysis.
Results
Hematologic recovery and early outcome
The results are presented in Table 2 . All the 97 patients who survived the first 21 days following transplantation and could be evaluated for hematological recovery achieved a full granulocyte recovery. A total of 91 patients could be evaluated for platelet recovery (six patients relapsed before reaching platelet counts above 25 Â 10 9 /l). Time to granulocyte and platelet recovery and time to discharge were significantly reduced in the group of patients who received PBSC as compared to BM (see Table 2 ).
Seven patients died while in CR. Four died early from infectious complications including sepsis (three patients) and viral encephalitis (one patient). Three patients died after day 100: one patient died from post-transfusion AIDS; one patient died from interstitial pneumonia related to rIL-2 administration; and one patient died from a secondary myelodysplastic syndrome. The cumulative incidence of TRM was 8% (95% confidence interval: 4-16%).
No death in CR was recorded in the group of 43 patients who received PBSC transplant.
Relapse, survival, and DFS
The median follow-up of survivors was 67 months (range 26-134). In all, 42 patients are alive including 40 patients in unmaintained CR. The 6-year overall survival was 44% (95% confidence interval: 34-53%). The 6-year DFS was 38% (95% confidence interval: 34-53%) as shown in Figure 1 . A total of 53 patients relapsed at a median of 6 months after ASCT (range: 2-64 months). The 6-year cumulative incidence of relapse was 53% (95% confidence interval: 44-64%) with a plateau at 60 months.
The median survival after relapse was 5 months. First CR duration affects survival after relapse (median 8 months vs 3 months in patients with CR1X1 year vs CR1o 1 year, respectively; P-valueo 0.02). Four patients who relapsed are currently alive in second CR including two patients who received allogeneic transplantation. One patient who achieved a second CR survived 135 months in continuous CR but died from pancreatic carcinoma.
In total, 18 patients survived more than 6 years in CR from the time of ASCT. Due to time selection, most of them had received BM grafts. None of them had unfavorable karyotype at the time of diagnosis (favorable: five patients; intermediate: eight patients; not done: five patients). Two of them developed myelodysplastic syndrome. No other late effects were observed.
Prognostic factors
Results of univariate analysis are summarized in Table 3 . Patients with favorable karyotype had better survival, DFS, and reduced relapse probability than patients with intermediate and unfavorable karyotypes. There was no significant difference in the outcome of patients with intermediate and unfavorable karyotypes. The stem cell source affected both survival and DFS, and the patients who received PBSC had the best outcome (see Figure 2) . A significant impact on DFS, but not on survival or relapse, was also observed with the use of HDAC prior to ASCT (one or two courses vs no HDAC) and use of TBI (vs no TBI). Initial hyperleucocytosis and the number of induction courses for CR had no impact on outcome. There was also no effect of the CD34 þ cells content of PBSC grafts.
According to multivariate analysis, only cytogenetic category and stem cell sources retained a significant prognostic impact on survival, DFS, and -to a less extent for stem cell source -on relapse risk (see Table 4 ). Table 2 Early outcome after ASCT 
Discussion
In this study, we reported the long-term results of a large single institution series of adult AML patients younger than 60 years and not eligible for allogeneic BMT who received ASCT in first CR.
The characteristics of the 101 patients reported here do not substantially differ from the characteristics of AML patients included in recent large multicenter studies with regard to major prognostic factors such as age, WBC at diagnosis, karyotype, or the number of induction courses to achieve CR. 3, 8, 27 In particular, the distribution of cytogenetic categories in our population was comparable to previous studies, which showed 20-30% of patients in the favorable group, 50-65% in the intermediate group, and 10-25% in the unfavorable group. 3, 8, 27, 28 The effects of time-selection bias 29 expected here since analysis in not by intent-to-treat may have been limited by the relatively short interval between CR and ASCT (3.5 months) in our study.
Our results confirm that the strong impact of cytogenetics on prognosis is not modified by the use of highdose chemotherapy with ASCT as previously shown in a retrospective study from the EBMT registry. 30 In our study, the patients with favorable karyotype had improved survival and DFS and less relapse than other categories. Even when excluding patients with t(15;17), 6-year DFS in the favorable group was 87% (95% confidence interval: 62-93%), which compares favorably with the results of similar patients treated with HDAC in a CALGB study. 31 This confirms the good results of ASCT for patients in the favorable category recently reported by Slovak et al. 32 On the other hand, the prognosis of patients in the unfavorable category was particularly dismal. Probably due to the small number of patients in this category, there was no significant difference with the patients in the 'intermediate' category. It is still unclear which subgroup of patients is more likely to benefit specifically from ASCT until such time as a randomized comparison including stratification based on cytogenetics is performed. However, our results suggest that for patients with t(8;21) or inv (16) , the effect of ASCT on long-term DFS is comparable to high dose ara-C.
The results show that high-dose chemotherapy with ASCT has become a safe procedure. Previous studies from other comparable centers 33 reported day 100 mortality of less than 5%. Our data suggest that a substantial improvement has been achieved over recent years. Indeed, in our series, no transplant-related death was recorded among the last 51 patients treated over the last 5 years. This reflects the recent progress of supportive care that includes Table 3 Univariate analysis of factors affecting 6-year probabilities of survival, DFS, and relapse improvements of anti-infectious treatments, transfusion, and the use of hematopoietic growth factors. Moreover, our results emphasize the importance of use of PBSCs in these improvements. No toxic death occurred in the group of patients who received PBSCs. This group showed a significant shortening of granulocyte and platelet recovery when compared to patients who received BM grafts. As a consequence, hospitalization duration has been significantly reduced as previously shown in patients transplanted for solid tumor and lymphomas. 11 This confirms the results of the few reports, mainly from registry studies, 12 which addressed the comparison of PBSC to BM grafts in patients with AML.
In the present study, the use of PBSC was independently associated with better survival and DFS by multivariate analysis. These results must be contemplated cautiously because of the limited size of the sample and, above all, because they originate from a historical comparison. PBSC transplants and BM transplants have been used in different time periods during which other parameters have changed (pre-transplant treatment, supportive care, etc.), representing possible sources of confounding factors. In these regards, the administration of HDAC before stem cell harvest in the PBSC group can account for the better results in this group. Only prospective randomized studies can definitively address this issue. Such a study is currently being conducted by the EORTC group. Apart from these limitations, our results provide important information: (1) substantial improvements of mortality and morbidity of ASCT observed with PBSC use have probably translated into improved survival and DFS, and (2) there is no increase of relapse to support previous concerns about superior leukemic contamination of PBSC grafts. 5 The long-term follow-up available here shows that long-term effects are rare after ASCT, mainly represented by the occurrence of secondary myelodysplastic syndrome in two patients. The outcome of patients who relapse is usually poor (median survival of 8 months after relapse). As described after conventional chemotherapy, the duration of CR1 is a major determinant of prognosis after relapse. 34, 35 In conclusion, our study confirms that high-dose chemotherapy with ASCT is able to provide long-term DFS when used as post-remission treatment of AML. The results underline the strong reduction of mortality and morbidity achieved with use of PBSC grafts, which leads to a significant improvement of patient outcome. Based on these data, the administration of sequential high-dose chemotherapy courses or the investigation of ASCT in elderly patients can be envisaged. Table 4 Multivariate analysis of factors affecting survival and DFS
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